The binding site of the dopamine D2 receptor, like that of other homologous G protein-coupled receptors, is contained within a water-accessible crevice formed among its seven membrane-spanning segments. We have developed a method to map systematically all the residues forming the surface of this binding-site crevice, and we have applied this method to the third membrane-spanning segment (M3). We mutated, one at a time, 23 residues in and flanking M3 to cysteine and expressed the mutant receptors heterologously. Ten of these mutants reacted with charged, hydrophilic, lipophobic, sulfhydryl-specific reagents, added extracellularly, and were protected from reaction by a reversible dopamine antagonist. Thus, the side chains of these residues are exposed in the binding-site crevice, which like M3 extends from the extracellular to the intracellular side of the membrane. The pattern of exposure is consistent with a short loop followed by six turns of an a helix.
Introduction
The dopamine receptors, like the homologous receptors for the biogenic amines and for acetylcholine, bind neurotransmitters present in the extracellular medium and couple this binding to the activation of intracellular G proteins Strader et al., 1994) . The binding sites of these receptors are formed among their seven, mostly hydrophobic, membrane-spanning segments (Oprian, 1992; Strader et al., 1994) and are accessible to charged, water-soluble agonists like dopamine. Thus, each of these binding sites is contained within a water-accessible crevice, the binding-site crevice, extending from the extracellular surface of the receptor into the plane of the membrane. The surface of this crevice is formed by residues that contact specific agonists and/or antagonists and other residues that may affect binding indirectly.
To identify the residues that form the surface of the binding-site crevice in the human D2 receptor, we have adapted a new approach, the substituted-cysteine accessibility method (SCAM; Akabas et al., 1992 Akabas et al., , 1994a . Consecutive residues in the membrane-spanning segments are mutated to cysteine, one at a time, and the mutant receptors are expressed in heterologous cells. The surface exposure of a cysteine is inferred from the irreversible effects of sulfhydryl-specific reagents on binding. Therefore, the method requires that binding still be measurable after the mutation to cysteine. In ligand-gated ion channels, the substitution by cysteine of individual residues in channel-forming membrane-spanning segments was very well tolerated (Akabas et al., 1992 (Akabas et al., , 1994a (Akabas et al., , 1994b Xu and Akabas, 1993) . If ligand binding to a cysteine-substitution mutant is near normal, it is likely that the structure of the mutant receptor is similar to that of wild type and that the substituted cysteine lies in a similar orientation to that of the wild-type residue.
In the membrane-spanning segments, the sulfhydryl of a cysteine can face either into the binding-site crevice, into the interior of the protein, or into the lipid bilayer; only sulfhydryls facing into the binding-site crevice should be accessible to hydrophilic, lipophobic, sulfhydryl-specific reagents ( Figure 1 ). For such reagents, we use derivatives of methanethiosulfonate (MTS): positively charged MTS ethylammonium (MTSEA) and MTS ethyltrimethylammonium (MTSET), and negatively charged MTS ethylsulfonate (MTSES; Stauffer and Karlin, 1994) . These reagents are about the same size as dopamine, with maximum dimensions of about 10 ,~, by 6 ~,. They form mixed disulfides with the cysteine sulfhydryl, covalently linking -SCH2CH2X, where X is NH3 +, N(CH3)3 +, or SO3-.
We use two criteria for identifying an engineered cysteine as being in the binding-site crevice: first, the reaction with an MTS reagent alters binding irreversibly ( Figure  1) ; second, this reaction is retarded by the presence of agonists or antagonists, A related approach has been used to identify residues lining the channels of the nicotinic acetylcholine receptor (Akabas et al., 1992 (Akabas et al., , 1994a , the y-aminobutyric acid type A receptor (Xu and Akabas, 1993) , and the cystic fibrosis transmembrane conductance regulator (Akabas et al., 1994b) . Covalent modification of substituted cysteines has also been used to study the structures of a number of bacterial membrane proteins (Falke et al., 1988; Todd et al., 1989; Altenbach et al., 1990; Jakes et al., 1990; Pakula and Simon, 1992; Jung et al., 1993) .
We previously found that antagonist binding to wild-type D2 receptor is irreversibly inhibited by MTSEA and MTSET and that Cys-118, in the third membrane-spanning segment (M3), is responsible for this sensitivity (Javitch et al., 1994) . We therefore used the mutant Cl18S, which is insensitive to MTS reagents, as the starting point for further mutation. Because we already identified one residue in M3 (Cys-118) as being exposed in the binding-site crevice and because another (Asp-114) also likely faces the crevice (Mansour et al., 1992) , we applied SCAM first to M3.
In the 13-adrenergic receptor, residues that contribute to binding have been identified in membrane-spanning segments M3, M5, M6, and M7: mutations of , and Phe-290 altered binding (Strader et al., 1994) ; and Trp-330 was affinity-labeled by an antag- onist derivative (Wong et al., 1988) . These 5 residues are identically conserved in all catecholamine receptors. In the dopamine D2 receptor, mutation of the residues that align with the first 3 above also altered the binding of dopamine agonists and antagonists (Cox et al., 1992; Mansour et al., 1992) . Completely conserved residues, however, cannot account for the profound differences in binding specificities among the catecholamine receptors. Additional residues must contribute to binding, either directly or indirectly. All the residues that contact ligand must be among those residues that form the surface of the binding-site crevice.
Results

Effects of Cysteine Substitution on Antagonist Binding
Starting with C 118S, we mutated to cysteine, one at a time, residues Asp-108 to in 
Reactions of the Mutants with MTSEA
Based on irreversible inhibition of binding, we infer that MTSEA reacted with cysteines at 11 of 22 positions tested ( Figure 2A ). The reversible antagonist sulpiride (10 I~M) retarded the reaction of MTSEA with each of the reactive mutants ( Figure 3 ). Based on our criteria and on the assumption that the cysteine side chains are in the same position as the wild-type side chains, the side chains of the following 10 residues are exposed in the binding- Vl15C. Cells were washed by filtration though 96-well multiscreen plates containing GFB filters (Millipore). In the wash buffer, sodium was replaced by choline to facilitate removal of residual sulpiride (Jarvie et al., 1987 Some substituted cysteines were markedly more sensitive to MTSEA than others ( Figure 2B ). To quantitate this, we determined the second-order rate constant for the decrease in binding ( Table 2 ). The most reactive cysteines are Cys-118 and those substituted for Val-111 and Vail 15. In a helical-net representation, these 3 residues cluster around Asp-114 ( Figure 4A ). Cysteines substituted for
Ser-121 and Ile-122, located closer to the cytoplasmic side than the highly reactive Cys-118, were of intermediate reactivity with MTSEA. Cysteines substituted for the 3 most extracellular, susceptible residues and the 3 most cytoplasmic, susceptible residues were the least reactive. Surprisingly, Leu-125 and Ser-129, putatively at the cytoplasmic end of M3 (Probst et al., 1992; Baldwin, 1993) , were accessible to MTSEA. The second-order rate constant (k) for each susceptible mutant was quantitated by incubating intact cells with four concentrations of MTSEA between 0.01 and 2.5 m M (all in great excess over the quantity of reactive sulfhydryls) for 2 rain. The extent of reaction was taken to be proportional to the extent of inhibition of binding, which followed pseudo-first-order kinetics as a function of MTSEA concentration. The pseudo-first-order rate constant was divided by 120 s to obtain the second-order rate constant. 
Discussion
Residues Exposed in the Binding-Site Crevice We used SCAM to identify residues exposed in the binding-site crevice. We make the following assumptions. The highly polar MTS reagents (Stauffer and Karlin, 1994) react only at the water-accessible surface of the protein. In the membrane-spanning segments, access of highly polar reagents to side chains is only through the binding-site crevice. The addition of -SCH2CH2X to a cysteine at the surface of the binding-site crevice alters binding irreversibly, and, reciprocally, competitive antagonists and agonists should retard the reaction with MTSEX. Based on these assumptions, on the irreversible inhibition of binding by MTSEA, and on the retardation of this reaction by sulpiride, we infer that 10 of the 22 residues tested are exposed in the binding-site crevice: Asp-108, Ile-109, Phe-110, Val- 111, .
MTSET (1 mM)
Mechanism of the Inhibition of Binding by Reaction with MTS Reagents
The inhibitory effects of the addition of -SCH2CH2X to the cysteine could be due to steric block, electrostatic repulsion, conformational changes, or a combination of these.
Given that the reaction of MTSEA with cysteine generates a positively charged side chain resembling the lysine side chain, and that YM-09151-2 is also positively charged, electrostatic repulsion must contribute to the inhibition of binding. Nevertheless, there are three lines of evidence which suggest that some of the engineered cysteines are close to bound YM-09151-2 and that steric overlap also contributes to the inhibition: first, dithiopyridine, which adds the neutralthiopyridine to Cys-118, inhibited the bind- ) . Thus, small changes in the size of the added -SCH2CH2X had a large effect on the resulting inhibition. Therefore, given that YM-09151-2 and N-methylspiperone bind to overlapping sites, Cys-118 is close to these sites. Third, the protection of the 10 residues in the binding-site crevice bythe antagonist sulpiride, which is similar chemically to YM-09151-2, is most simply explained by their proximity to the sulpiride-and YM-09151-2-binding site. Nevertheless, not every one of these residues need contact sulpiride; sulpiride could protect residues deeper in the crevice by binding above them and blocking the passage of MTSEA from the extracellular medium to the cytoplasmic end of the crevice. In addition, we cannot rule out indirect effects through propagated structural changes for either inhibition by the MTS reagents or protection by sulpiride.
It is clear for D108C that there is an electrostatic component to the alteration of binding due to the addition of -SCH2CH2X. Replacement of the aspartate by cysteine in D108C decreased affinity 4-fold (Table 1) ; modification by MTSES, which restores negative charge to the side chain, increased the affinity 2-fold, increasing binding ( Figure  5B ). In contrast, modification by the positively charged MTSEA (Figures 2A and 2B ) and MTSET ( Figure 5A ) inhibited binding.
The Secondary Structure of the Binding-Site Crevice
To infer a secondary structure, we must assume that, if binding to a mutant is not affected by the MTS reagents, then no reaction has occurred and that the side chain at this position is not exposed in the binding-site crevice. Because the exposed residues from Phe-110 to Ser-129 are contained within an arc of 140 ° in a helical wheel representation of M3 ( Figure 4B ), these residues would be located on one side of an ~ helix ( Figure 4A) . Unless, at the extracellular end of M3, an arc of 300 ° is exposed and protected by sulpiride, Asp-108 and Ile-109 are not likely to be in an a-helical conformation and may be part of the loop between M2 and M3. An R-helical conformation of M3 is consistent with the accepted structures of rhodopsin (Baldwin, 1993; Schertler et al., 1993) and bacteriorhodopsin (Henderson et al., 1990) .
Asp-114 is the only residue in M3 of the D2 receptor, and of homologous biogenic amine receptors, previously identified as contributing to binding. Asp-114 likely plays an important role in the binding of the positively charged ammonium of catecholamines and competitive antagonists of these ligands (Mansour et al., 1992; Strader et al., 1994) . Although we could not determine directly the accessibility of Asp-114, given the pattern of accessibility of its neighbors, it almost certainly faces the binding-site crevice. In a helical-net representation, the most reactive cysteines, Cys-118 and those substituted for Val-111 and Va1-115, cluster around Asp-114 ( Figure 4A ).
In addition to the conserved Asp-114, the exposed Val-115 aligns with muscarinic receptor Tyr-148, implicated in the binding of agonists (Wess et al., 1991) , and the exposed Phe-110 aligns with rhodopsin Glu-113, thought to provide the counterion for the retinal Lys-296 protonated Schiff base (Sakmar et al., 1989; Nathans, 1990; Zhukovsky and Oprian, 1990 ). In the different G protein-coupled receptors, aligned residues may be exposed in the binding-site crevices and yet make more or less crucial contributions to binding in the different receptors. In the D2 receptor, except for Asp-114, none of the specific side chains in M3 are indispensable for the binding of the antagonist [3H]YM-09151-2, because the mutation of the residues to cysteine decreased the affinity at most 5-fold. V115C had the lowest affinity, and the rate of reaction of MTSEA was the greatest in this mutant, consistent with the Va1-115 side chain being close to bound ligand. Conclusions about the surface accessibility and proximity to bound ligand of a side chain could not be made simply on the basis of the effect of mutagenesis on the binding of YM-09151-2; e.g., although Leu-113 is not exposed in the binding-site crevice (Figure 4 ), the mutant L113C had an affinity for YM-09151-2 nearly 4-fold lower than did Cl18S.
The residues exposed in the binding-site crevice span M3 from the extracellular end to the intracellular end. MTSEA reacted with cysteines substituted for Leu-125 and Ser-129, putatively at the cytoplasmic end of M3 (Probst et al., 1992; Baldwin, 1993) . The rate constant of the reaction with these residues was roughly one-half that seen at the most extracellular end of M3, suggesting that access deep in the crevice is not dramatically impaired. It is possible that the binding-site crevice extends to the cytoplasmic end of M3, and, perhaps, provides a water-accessible path from the extracellular medium to the cytoplasm.
Electrostatic Potential in the Binding-Site Crevice MTSES did not react with cysteines substituted for residues more cytoplasmic than Val-11 t ( Figure 5B ), This is consistent with a negative electrostatic potential in the binding-site crevice, owing in part to the negative charge of Asp-114 (Javitch et al., 1994) . However, MTSES reacted with the mutants D108C, I109C, F110C, and V111C (Figure 5B) . At 1109C, F110C, and V111C, 10 mM MTSES inhibited binding nearly as much as 1 mM MTSET ( Figures  5A and 5B) . Because 1 mM MTSET and 10 mM MTSES are equireactive with simple thiols in solution (Stauffer and Karlin, 1994) , the rates of reaction of MTSET and MTSES with the residues located near the extracellular end of M3 are similar; this indicates that the electrostatic potential near these residues is not as negative as it is below Val-111.
Comparison of Reactions with MTSEA and MTSET
When adjusted for the rate constants for their reactions with simple thiols in solution (Stauffer and Karlin, 1994) , the reaction of MTSEA with cysteines in the binding-site crevice is accelerated approximately 10-fold relative to that of MTSET (Figures 2A and 2B ; Figure 5A ). MTSEA, like dopamine, contains an ethylammonium group, and it could be the affin ity of this group for the dopamine-binding site that accelerates the reaction of MTSEA, especially with the most reactive mutants, V111C and Vl15C, and with wild-type receptor containing Cys-118. MTSEA is also slightly smaller than MTSET. This difference probably accounts for the susceptibility of 1122C to MTSEA but not to MTSET.
Binding-Site Specificity
The known crucial residues in catecholamine receptors are highly conserved and therefore not likely to account for the differences in binding specificities among these receptors. These differences in specificity are particularly marked for antagonists and synthetic agonists and occur eve n among receptor subtypes. For example, the antagonist raclopride has a 20-fold higher affinity for the D2 than for the D4 receptor, and the antagonist clozapine has a 15-fold higher affinity for the D4 than for the D2 receptor . The residues that determine these differences in specificity are likely to be among those identified by SCAM as exposed in the binding-site crevice. Thus, while 8 residues in M3 differ between the dopamine D2 and D4 receptors (Grandy et al., 1989; Van Tol et al., 1991 ; Probst et al., 1992) , only 3 of these, Ile-109, Phe-110, and Val-111, face the binding-site crevice in the D2 receptor. If M3 contributes to the pharmacological differences between these receptors, 1 or more of these 3 residues, or their counterparts in the D4 receptor, might directly interact with these ligands. Finally, the residues identified by SCAM as facing the binding-site crevice are novel targets for new therapeutic agents.
Experimental Procedures
Site-Directed Mutagenesis
The coding region of the D2 receptor cDNA was subcloned at the EcoRI site into pcDNA1/Amp (Invitrogen), yielding the plasmid pcD2, and into pAlter-1 (Promega), yielding pAIterD2. Oligonucleotides were synthesized to generate the appropriate cysteine mutation and to introduce simultaneously a silent restriction site. The Altered Sites Mutagenesis System (Promega) was used to introduce the desired mutation. Mutations were identified using restriction mapping and confirmed by DNA sequencing. An appropriate cassette containing the mutation was sequenced in its entirety and subcloned into pcD2 to generate the appropriate mutant expression plasmid. Mutants are named as wild-type residue-residue number-mutant residue, with the residues given in the single-letter code.
Transient Transfection
HEK 293 cells were grown in DMEM/F12 (1:1) containing 3.15 g/I glucose (Specialty Media) in 10% bovine calf serum (Hyclone) at 37°C and 5°/0 CO2. HEK 293 cells at 60%-80% confluence in 35 mm dishes were cotransfected with 0.67 p.g of pcD2 or mutant pcD2 and 0.13 ~g of pRSVTag using 5 I11 of lipofectamine (GIBCO) and 1 ml of OPTIMEM (GIBCO). At 5 hr after transfection, the plates were diluted with 1 ml of media containing 20% bovine calf serum; 24 hr after transfection, the media was changed; 48 hr after transfection, cells were washed with PBS (8.1 mM NaH2PO,, 1.5 mM KH2PO4, 138 mM NaCI, 2.7 mM KCI [pH 7.2]), briefly treated with PBS containing 5 mM EDTA, and then dissociated in PBS. Cells were pelleted at 1000 x g for 5 rain at 4°C and resuspended for binding or treatment with MTS reagents.
[3H]YM-09151-2 Binding
For saturation binding, whole cells were resuspended in 450 ~.1 of PBS containing 0.9 mM CaCI2, 0.5 mM MgCI2, and 0.5 mM EDTA at pH 7.4 (buffer A). Cells were then diluted 50-fold with buffer A. Binding of [3H]YM-09151-2 (Dupont/NEN) was determined by a modification of reported procedures (Niznik et al., 1985; Javitch et al., 1994) . Triplicate borosilicate tubes contained six different concentrations of [3H]YM-09151-2 between 5 and 400 pM in buffer A with 900 I11 of cell suspension in a final volume of 2 ml. The mixture was incubated at room temperature for 60 rain and then filtered using a Brandel cell harvester through Whatman 934AH glass fiber filters (Brandel). The filter was washed twice with 5 ml of 10 mM Tris-HCI, 120 mM NaCI (pH 7.4) at room temperature. 
Reactions with MTS Reagents
For treatment with MTS reagents, whole cells were resuspended in 450 p.I of buffer B (25 mM HEPES, 140 mM NaCI, 5.4 mM KCI, 1 mM EDTA, 0.006% bovine serum albumin [pH 7.4]). Aliquots (50 ~1) of cell suspension were incubated with MTS reagents at the stated concentrations at room temperature for 2 rain. Cell suspensions were then diluted 60-fold, and 900 p.I aliquots were used to assay for [3H]YM-09151-2 (100 pM) binding as described above, using buffer B for binding buffer. Equivalent results were obtained with buffer A and buffer B for both binding and MTS treatment. The fractional inhibition was calculated as 1 -[(specific binding after MTS reagent)/(specific binding without reagent)[. We used the SPSS for Windows (SPSS, Inc.) statistical software to analyze the effects of the MTS reagents by one-way ANOVA according to Student-Newman-Keuls criteria (p < .05).
